NASDAQ:KIDS

OrthoPediatrics Competitors

$49.55
+0.01 (+0.02 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$49.05
Now: $49.55
$50.24
50-Day Range
$44.26
MA: $50.09
$56.52
52-Week Range
$38.01
Now: $49.55
$57.42
Volume71,486 shs
Average Volume207,531 shs
Market Capitalization$974.05 million
P/E RatioN/A
Dividend YieldN/A
Beta0.67

Competitors

OrthoPediatrics (NASDAQ:KIDS) Vs. IRTC, GKOS, CMD, NUVA, MMSI, and ATRC

Should you be buying KIDS stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to OrthoPediatrics, including iRhythm Technologies (IRTC), Glaukos (GKOS), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI), and AtriCure (ATRC).

OrthoPediatrics (NASDAQ:KIDS) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for OrthoPediatrics and iRhythm Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrthoPediatrics00303.00
iRhythm Technologies04702.64

OrthoPediatrics currently has a consensus target price of $55.80, suggesting a potential upside of 12.61%. iRhythm Technologies has a consensus target price of $212.6667, suggesting a potential upside of 60.19%. Given iRhythm Technologies' higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than OrthoPediatrics.

Valuation and Earnings

This table compares OrthoPediatrics and iRhythm Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrthoPediatrics$72.55 million13.43$-13,730,000.00($0.87)-56.95
iRhythm Technologies$214.55 million18.04$-54,570,000.00($2.16)-61.46

OrthoPediatrics has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

OrthoPediatrics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Profitability

This table compares OrthoPediatrics and iRhythm Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrthoPediatrics-34.26%-11.57%-8.79%
iRhythm Technologies-20.97%-28.89%-15.11%

Insider & Institutional Ownership

71.7% of OrthoPediatrics shares are owned by institutional investors. 33.6% of OrthoPediatrics shares are owned by insiders. Comparatively, 3.1% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

OrthoPediatrics beats iRhythm Technologies on 8 of the 14 factors compared between the two stocks.

OrthoPediatrics (NASDAQ:KIDS) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Valuation and Earnings

This table compares OrthoPediatrics and Glaukos' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrthoPediatrics$72.55 million13.43$-13,730,000.00($0.87)-56.95
Glaukos$236.98 million16.06$15.42 million($0.10)-831.30

Glaukos has higher revenue and earnings than OrthoPediatrics. Glaukos is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

71.7% of OrthoPediatrics shares are owned by institutional investors. 33.6% of OrthoPediatrics shares are owned by insiders. Comparatively, 8.7% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for OrthoPediatrics and Glaukos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrthoPediatrics00303.00
Glaukos16102.00

OrthoPediatrics currently has a consensus target price of $55.80, suggesting a potential upside of 12.61%. Glaukos has a consensus target price of $66.3750, suggesting a potential downside of 20.16%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, equities analysts clearly believe OrthoPediatrics is more favorable than Glaukos.

Profitability

This table compares OrthoPediatrics and Glaukos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrthoPediatrics-34.26%-11.57%-8.79%
Glaukos-33.61%-7.99%-5.87%

Risk and Volatility

OrthoPediatrics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.

Summary

Glaukos beats OrthoPediatrics on 8 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Cantel Medical and OrthoPediatrics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cantel Medical$1.02 billion3.48$13.71 million$1.6550.76
OrthoPediatrics$72.55 million13.43$-13,730,000.00($0.87)-56.95

Cantel Medical has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

95.0% of Cantel Medical shares are owned by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are owned by institutional investors. 10.7% of Cantel Medical shares are owned by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Cantel Medical and OrthoPediatrics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cantel Medical12102.00
OrthoPediatrics00303.00

Cantel Medical presently has a consensus price target of $71.50, suggesting a potential downside of 14.64%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than Cantel Medical.

Profitability

This table compares Cantel Medical and OrthoPediatrics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cantel Medical3.38%11.19%4.10%
OrthoPediatrics-34.26%-11.57%-8.79%

Volatility & Risk

Cantel Medical has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Summary

Cantel Medical beats OrthoPediatrics on 9 of the 14 factors compared between the two stocks.

NuVasive (NASDAQ:NUVA) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares NuVasive and OrthoPediatrics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuVasive$1.17 billion3.02$65.23 million$2.4727.82
OrthoPediatrics$72.55 million13.43$-13,730,000.00($0.87)-56.95

NuVasive has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

71.7% of OrthoPediatrics shares are owned by institutional investors. 0.9% of NuVasive shares are owned by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for NuVasive and OrthoPediatrics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NuVasive27702.31
OrthoPediatrics00303.00

NuVasive presently has a consensus price target of $64.8667, suggesting a potential downside of 5.59%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than NuVasive.

Profitability

This table compares NuVasive and OrthoPediatrics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NuVasive-0.84%8.00%3.06%
OrthoPediatrics-34.26%-11.57%-8.79%

Volatility & Risk

NuVasive has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Summary

NuVasive beats OrthoPediatrics on 8 of the 14 factors compared between the two stocks.

Merit Medical Systems (NASDAQ:MMSI) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Merit Medical Systems and OrthoPediatrics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$994.85 million3.44$5.45 million$1.4642.12
OrthoPediatrics$72.55 million13.43$-13,730,000.00($0.87)-56.95

Merit Medical Systems has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

99.5% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are owned by institutional investors. 4.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Merit Medical Systems and OrthoPediatrics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merit Medical Systems01702.88
OrthoPediatrics00303.00

Merit Medical Systems presently has a consensus price target of $64.3750, suggesting a potential upside of 4.67%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than Merit Medical Systems.

Profitability

This table compares Merit Medical Systems and OrthoPediatrics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merit Medical Systems-3.05%9.02%4.91%
OrthoPediatrics-34.26%-11.57%-8.79%

Volatility & Risk

Merit Medical Systems has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Summary

Merit Medical Systems beats OrthoPediatrics on 9 of the 14 factors compared between the two stocks.

AtriCure (NASDAQ:ATRC) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares AtriCure and OrthoPediatrics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$230.81 million13.01$-35,190,000.00($1.07)-61.59
OrthoPediatrics$72.55 million13.43$-13,730,000.00($0.87)-56.95

OrthoPediatrics has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.7% of AtriCure shares are owned by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are owned by institutional investors. 5.8% of AtriCure shares are owned by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for AtriCure and OrthoPediatrics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtriCure00703.00
OrthoPediatrics00303.00

AtriCure presently has a consensus price target of $66.00, suggesting a potential upside of 0.15%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given OrthoPediatrics' higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than AtriCure.

Volatility & Risk

AtriCure has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Profitability

This table compares AtriCure and OrthoPediatrics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtriCure-21.74%-14.83%-7.77%
OrthoPediatrics-34.26%-11.57%-8.79%

Summary

OrthoPediatrics beats AtriCure on 7 of the 13 factors compared between the two stocks.


OrthoPediatrics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$132.76+1.3%$3.87 billion$214.55 million-69.51
Glaukos logo
GKOS
Glaukos
0.9$83.13+3.3%$3.81 billion$236.98 million-50.38Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Cantel Medical logo
CMD
Cantel Medical
1.3$83.76+0.5%$3.54 billion$1.02 billion99.72Insider Selling
NuVasive logo
NUVA
NuVasive
1.1$68.71+1.7%$3.53 billion$1.17 billion-312.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50+1.5%$3.42 billion$994.85 million-116.04News Coverage
AtriCure logo
ATRC
AtriCure
1.5$65.90+1.0%$3.00 billion$230.81 million-57.30
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$60.13+0.2%$2.50 billion$13.82 million-30.68
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72+0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14+0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60+1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95+2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48+4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13+0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72+5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76+0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00+0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44+2.0%$1.06 billion$117.23 million55.31
Cerus logo
CERS
Cerus
1.7$6.13+1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77+1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61+0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87+1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14+0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49+1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94+2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26+0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81+1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00+1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21+0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55+1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12+1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07+0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50+3.9%$415.95 million$4.17 million-17.52News Coverage
Soliton logo
SOLY
Soliton
1.1$18.25+0.1%$386.90 millionN/A-24.33
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.90+0.2%$385.05 million$24.95 million-26.97
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.73+0.7%$373.97 million$198.38 million24.87
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.20+0.5%$370.85 million$2.84 million0.00
Apyx Medical logo
APYX
Apyx Medical
1.0$9.50+3.7%$326.02 million$28.15 million-20.21Analyst Downgrade
Gap Up
Neuronetics logo
STIM
Neuronetics
1.5$12.79+2.5%$324.97 million$62.66 million-7.61
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54+1.0%$319.17 million$46.90 million27.62News Coverage
DarioHealth logo
DRIO
DarioHealth
1.1$20.62+3.9%$317.45 million$7.56 million-2.58Gap Up
IRadimed logo
IRMD
IRadimed
1.5$24.04+3.0%$295.96 million$38.52 million75.13News Coverage
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.10+2.2%$260.86 million$220,000.0011.23
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.53+0.7%$227.19 million$8.34 million-2.22
Titan Medical logo
TMDI
Titan Medical
1.2$1.82+7.1%$199.34 millionN/A182.00Analyst Report
Analyst Revision
News Coverage
Gap Down
TELA Bio logo
TELA
TELA Bio
2.1$13.72+0.0%$198.12 million$15.45 million-4.71
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.